Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Myriad Genetics (MYGN) EBITDA (2016 - 2025)

Historic EBITDA for Myriad Genetics (MYGN) over the last 17 years, with Q3 2025 value amounting to -$23.3 million.

  • Myriad Genetics' EBITDA fell 1650.0% to -$23.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$420.5 million, marking a year-over-year decrease of 26312.61%. This contributed to the annual value of -$123.5 million for FY2024, which is 5202.02% up from last year.
  • As of Q3 2025, Myriad Genetics' EBITDA stood at -$23.3 million, which was down 1650.0% from -$329.2 million recorded in Q2 2025.
  • Myriad Genetics' 5-year EBITDA high stood at -$17.8 million for Q2 2022, and its period low was -$329.2 million during Q2 2025.
  • Its 5-year average for EBITDA is -$57.5 million, with a median of -$39.0 million in 2024.
  • Per our database at Business Quant, Myriad Genetics' EBITDA surged by 6954.61% in 2021 and then plummeted by 80191.78% in 2025.
  • Quarter analysis of 5 years shows Myriad Genetics' EBITDA stood at -$43.1 million in 2021, then fell by 21.11% to -$52.2 million in 2022, then skyrocketed by 39.85% to -$31.4 million in 2023, then dropped by 24.2% to -$39.0 million in 2024, then surged by 40.26% to -$23.3 million in 2025.
  • Its EBITDA stands at -$23.3 million for Q3 2025, versus -$329.2 million for Q2 2025 and -$29.0 million for Q1 2025.